Skip to main content
Top
Published in: Investigational New Drugs 3/2013

01-06-2013 | PRECLINICAL STUDIES

Dual modulation of JNK and Akt signaling pathways by chaetoglobosin K in human lung carcinoma and ras-transformed epithelial cells

Authors: Amna Ali, Tatyana S. Sidorova, Diane F. Matesic

Published in: Investigational New Drugs | Issue 3/2013

Login to get access

Summary

Chaetoglobosin K (ChK) is a natural product that inhibits anchorage-dependent and anchorage-independent growth of ras-transformed cells, prevents tumor-promoter disruption of cell-cell communication, and reduces Akt activation in tumorigenic cells. This study demonstrates how ChK modulates the JNK pathway in ras-transformed and human lung carcinoma cells and investigates regulatory mechanisms controlling ChK’s effect on the Akt and JNK signaling pathways. Human lung carcinoma and ras-transformed epithelial cell lines treated with ChK or vehicle for varying times were assayed for cell growth or extracted for total proteins for western blot analysis using phosphorylation site-specific antibodies to monitor changes in activation of JNK, Akt, and other signaling enzymes. Results show that ChK inhibited both Akt and JNK phosphorylation at key activation sites in ras-transformed cells as well as human lung carcinoma cells. Downstream effectors of both kinases were accordingly affected. Direct upstream kinases of JNK were not affected by ChK. Wortmannin and LY294002, two PI3 kinase inhibitors, inhibited Akt but not JNK phosphorylation in ras-transformed cells. This report establishes the dual inhibitory effect of ChK on both the Akt and JNK signaling pathways in ras-transformed epithelial and human carcinoma cells. The unique effect of ChK on these two key pathways involved in carcinogenesis earmarks ChK for further studies to determine its molecular target(s) and in vivo anti-tumor potential.
Literature
1.
go back to reference Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI et al (1984) The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312:513–516PubMedCrossRef Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI et al (1984) The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312:513–516PubMedCrossRef
2.
go back to reference Jou YS, Layhe B, Matesic DF, Chang CC, de Feijter AW, Lockwood L et al (1995) Inhibition of gap junctional intercellular communication and malignant transformation of rat liver epithelial cells by neu oncogene. Carcinogenesis 16:311–317PubMedCrossRef Jou YS, Layhe B, Matesic DF, Chang CC, de Feijter AW, Lockwood L et al (1995) Inhibition of gap junctional intercellular communication and malignant transformation of rat liver epithelial cells by neu oncogene. Carcinogenesis 16:311–317PubMedCrossRef
3.
go back to reference Adjei AA (2001) Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93:1062–1074PubMedCrossRef Adjei AA (2001) Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93:1062–1074PubMedCrossRef
4.
go back to reference Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M et al (2002) Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297:102–104PubMedCrossRef Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M et al (2002) Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297:102–104PubMedCrossRef
5.
6.
go back to reference Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M et al (2006) Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 24:3831–3837PubMedCrossRef Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M et al (2006) Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 24:3831–3837PubMedCrossRef
7.
go back to reference Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21:2237–2246PubMedCrossRef Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21:2237–2246PubMedCrossRef
8.
go back to reference Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149–2158PubMedCrossRef Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149–2158PubMedCrossRef
9.
go back to reference Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J et al (2004) Targeted therapies for cancer 2004. Am J Clin Pathol 122:598–609PubMedCrossRef Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J et al (2004) Targeted therapies for cancer 2004. Am J Clin Pathol 122:598–609PubMedCrossRef
10.
go back to reference Xiong HQ (2004) Molecular targeting therapy for pancreatic cancer. Cancer Chemother Pharmacol 54:S69–S77PubMed Xiong HQ (2004) Molecular targeting therapy for pancreatic cancer. Cancer Chemother Pharmacol 54:S69–S77PubMed
11.
go back to reference Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765PubMedCrossRef Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765PubMedCrossRef
12.
13.
go back to reference Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P et al (1997) Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89:457–467PubMedCrossRef Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P et al (1997) Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89:457–467PubMedCrossRef
15.
go back to reference Vivanco I, Sawyers CI (2002) The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2:489–501PubMedCrossRef Vivanco I, Sawyers CI (2002) The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2:489–501PubMedCrossRef
16.
go back to reference Stokoe D, Stephens LR, Copeland T, Gaffney PRJ, Reese CB, Painter GF et al (1997) Dual role of the phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 277:567–570PubMedCrossRef Stokoe D, Stephens LR, Copeland T, Gaffney PRJ, Reese CB, Painter GF et al (1997) Dual role of the phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 277:567–570PubMedCrossRef
17.
go back to reference Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI et al (2004) Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 64:4394–4399PubMedCrossRef Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI et al (2004) Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 64:4394–4399PubMedCrossRef
19.
go back to reference Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL et al (2001) AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159:431–437PubMedCrossRef Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL et al (2001) AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159:431–437PubMedCrossRef
20.
go back to reference Segrelles C, Ruiz S, Perez P, Murga C, Santos M, Budunova IV et al (2002) Functional roles of Akt signaling in mouse skin tumorigenesis. Oncogene 21:53–64PubMedCrossRef Segrelles C, Ruiz S, Perez P, Murga C, Santos M, Budunova IV et al (2002) Functional roles of Akt signaling in mouse skin tumorigenesis. Oncogene 21:53–64PubMedCrossRef
21.
go back to reference Affara NI, Schanbacher BL, Mihm MJ, Cook AC, Pei P, Mallery SR et al (2004) Activated Akt-1 in specific cell populations during multi-stage skin carcinogenesis. Anticancer Res 24:2773–2782PubMed Affara NI, Schanbacher BL, Mihm MJ, Cook AC, Pei P, Mallery SR et al (2004) Activated Akt-1 in specific cell populations during multi-stage skin carcinogenesis. Anticancer Res 24:2773–2782PubMed
22.
go back to reference Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R et al (2002) Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8:1168–1171PubMed Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R et al (2002) Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8:1168–1171PubMed
23.
go back to reference Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S et al (2004) Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64:5232–5236PubMedCrossRef Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S et al (2004) Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64:5232–5236PubMedCrossRef
24.
go back to reference Antonyak MA, Kenyon LC, Godwin AK, James DC, Emlet DR, Okamoto I et al (2002) Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene 21:5038–5046PubMedCrossRef Antonyak MA, Kenyon LC, Godwin AK, James DC, Emlet DR, Okamoto I et al (2002) Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene 21:5038–5046PubMedCrossRef
25.
go back to reference Engelberg D (2004) Stress-activated protein kinases - tumor suppressors or tumor initiators? Semin Cancer Biol 14:271–282PubMedCrossRef Engelberg D (2004) Stress-activated protein kinases - tumor suppressors or tumor initiators? Semin Cancer Biol 14:271–282PubMedCrossRef
26.
go back to reference Khatlani TS, Wislez M, Sun M, Srinivas H, Iwanaga K, Ma L et al (2007) c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells. Oncogene 26:2658–2666PubMedCrossRef Khatlani TS, Wislez M, Sun M, Srinivas H, Iwanaga K, Ma L et al (2007) c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells. Oncogene 26:2658–2666PubMedCrossRef
27.
go back to reference Cutler HG, Crumley F, Cox R (1980) Chaetoglobosin K: a new plant growth inhibitor and toxin from Diplodia macrospora. J Agric Food Chem 28:139–142PubMedCrossRef Cutler HG, Crumley F, Cox R (1980) Chaetoglobosin K: a new plant growth inhibitor and toxin from Diplodia macrospora. J Agric Food Chem 28:139–142PubMedCrossRef
28.
go back to reference Tikoo A, Cutler H, Lo SH, Chen LB, Maruta H (1999) Treatment of Ras-induced cancers by the F-actin cappers Tensin and Chaetoglobosin K, in combination with the Caspase-1 inhibitor N1445. Cancer J Sci Am 5:293–300PubMed Tikoo A, Cutler H, Lo SH, Chen LB, Maruta H (1999) Treatment of Ras-induced cancers by the F-actin cappers Tensin and Chaetoglobosin K, in combination with the Caspase-1 inhibitor N1445. Cancer J Sci Am 5:293–300PubMed
29.
go back to reference Matesic DF, Villio KN, Folse SL, Garcia EL, Cutler SJ, Cutler HG (2006) Inhibition of cytokinesis and Akt phosphorylation by chaetoglobosin K in ras-transformed epithelial cells. Cancer Chemother Pharmocol 57:741–754CrossRef Matesic DF, Villio KN, Folse SL, Garcia EL, Cutler SJ, Cutler HG (2006) Inhibition of cytokinesis and Akt phosphorylation by chaetoglobosin K in ras-transformed epithelial cells. Cancer Chemother Pharmocol 57:741–754CrossRef
30.
go back to reference Matesic DF, Blommel ML, Sunman JA, Cutler SJ, Cutler HG (2001) Prevention of organochlorine-induced inhibition of gap junctional communication by chaetoglobosin K in astrocytes. Cell Biol Toxicol 17:395–408PubMedCrossRef Matesic DF, Blommel ML, Sunman JA, Cutler SJ, Cutler HG (2001) Prevention of organochlorine-induced inhibition of gap junctional communication by chaetoglobosin K in astrocytes. Cell Biol Toxicol 17:395–408PubMedCrossRef
31.
go back to reference Sidorova TS, Matesic DF (2008) Protective effect of the natural product, Chaetoglobosin K, on lindane- and dieldrin-induced changes in astroglia: identification of activated signaling pathways. Pharm Res 25:1297–1308PubMedCrossRef Sidorova TS, Matesic DF (2008) Protective effect of the natural product, Chaetoglobosin K, on lindane- and dieldrin-induced changes in astroglia: identification of activated signaling pathways. Pharm Res 25:1297–1308PubMedCrossRef
32.
go back to reference Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R et al (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351–1356PubMedCrossRef Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R et al (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351–1356PubMedCrossRef
33.
go back to reference Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098–1101PubMedCrossRef Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098–1101PubMedCrossRef
34.
go back to reference Kwon T, Kwon DY, Chun J, Kim JH, Kang SS (2000) Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at serine 71 of Rac1. J Biol Chem 275:423–428PubMedCrossRef Kwon T, Kwon DY, Chun J, Kim JH, Kang SS (2000) Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at serine 71 of Rac1. J Biol Chem 275:423–428PubMedCrossRef
35.
go back to reference Murga C, Zohar M, Teramoto H, Gutkind JS (2002) Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-kappaB. Oncogene 21:207–216PubMedCrossRef Murga C, Zohar M, Teramoto H, Gutkind JS (2002) Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-kappaB. Oncogene 21:207–216PubMedCrossRef
36.
go back to reference Zhang QG, Wang XT, Han D, Yin XH, Zhang GY, Xu TL (2006) Akt inhibits MLK3/JNK3 signaling by inactivating Rac1: a protective mechanism against ischemic brain injury. J Neurochem 98:1886–1898PubMedCrossRef Zhang QG, Wang XT, Han D, Yin XH, Zhang GY, Xu TL (2006) Akt inhibits MLK3/JNK3 signaling by inactivating Rac1: a protective mechanism against ischemic brain injury. J Neurochem 98:1886–1898PubMedCrossRef
37.
go back to reference Logan MR, Mandato CA (2006) Regulation of the actin cytoskeleton by PIP2 in cytokinesis. Biol Cell 98:377–388PubMedCrossRef Logan MR, Mandato CA (2006) Regulation of the actin cytoskeleton by PIP2 in cytokinesis. Biol Cell 98:377–388PubMedCrossRef
38.
go back to reference Canman JC, Lewellyn L, Laband K, Smerdon SJ, Desai A, Bowerman B, Oegema K (2008) Inhibition of Rac by the GAP activity of centralspindlin is essential for cytokinesis. Science 322:1543–1546PubMedCrossRef Canman JC, Lewellyn L, Laband K, Smerdon SJ, Desai A, Bowerman B, Oegema K (2008) Inhibition of Rac by the GAP activity of centralspindlin is essential for cytokinesis. Science 322:1543–1546PubMedCrossRef
39.
go back to reference Lim CP, Cao X (1999) Serine phosphorylation and negative regulation of Stat3 by JNK. J Biol Chem 274:31055–31061PubMedCrossRef Lim CP, Cao X (1999) Serine phosphorylation and negative regulation of Stat3 by JNK. J Biol Chem 274:31055–31061PubMedCrossRef
40.
go back to reference Rawlings JS, Rosler KM, Harrison DA (2004) The JAK/STAT signaling pathway. J Cell Sci 117:1281–1283PubMedCrossRef Rawlings JS, Rosler KM, Harrison DA (2004) The JAK/STAT signaling pathway. J Cell Sci 117:1281–1283PubMedCrossRef
41.
go back to reference Wong MK, Lo AI, Lam B, Lam WK, Ip MS, Ho JC (2010) Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 65:1023–1028PubMedCrossRef Wong MK, Lo AI, Lam B, Lam WK, Ip MS, Ho JC (2010) Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 65:1023–1028PubMedCrossRef
Metadata
Title
Dual modulation of JNK and Akt signaling pathways by chaetoglobosin K in human lung carcinoma and ras-transformed epithelial cells
Authors
Amna Ali
Tatyana S. Sidorova
Diane F. Matesic
Publication date
01-06-2013
Publisher
Springer US
Published in
Investigational New Drugs / Issue 3/2013
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-012-9883-x

Other articles of this Issue 3/2013

Investigational New Drugs 3/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine